BLR&D Research Career Scientist Application

BLR

• 批准号: 10047700
• 负责人: Timothy S Kern
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-10-01 至 2021-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10047700
• 关键词: Acetylation; Adult; Affect; Aldehyde Reductase; Animals; Area; Basic Science; Blindness; Blood Vessels; Canis familiaris; Clinical Research; Clinical Trials; Complications of Diabetes Mellitus; Development; Diabetes Mellitus; Diabetic Retinopathy; Disease; Epigenetic Process; Extravasation; Eye; Failure; G-Protein-Coupled Receptors; Goals; Inflammation; Inflammatory; Investigation; Journals; Laboratories; Learning; Lesion; Leukocytes; Memory; Metabolic; Patients; Pharmaceutical Preparations; Pharmacology; Photoreceptors; Play; Regulation; Reporting; Research; Retina; Retinal Diseases; Retinal Photoreceptors; Role; Scientist; Seminal; System; Testing; Translating; Veterans; Vision; Work; career; clinical care; diabetic; diabetic patient; glycemic control; inhibitor/antagonist; insight; light intensity; macular edema; novel; Acetylation; Adult; Affect; Aldehyde Reductase; Animals; Area; Basic Science; Blindness; Blood Vessels; Canis familiaris; Clinical Research; Clinical Trials; Complications of Diabetes Mellitus; Development; Diabetes Mellitus; Diabetic Retinopathy; Disease; Epigenetic Process; Extravasation; Eye; Failure; G-Protein-Coupled Receptors; Goals; Inflammation; Inflammatory; Investigation; Journals; Laboratories; Learning; Lesion; Leukocytes; Memory; Metabolic; Patients; Pharmaceutical Preparations; Pharmacology; Photoreceptors; Play; Regulation; Reporting; Research; Retina; Retinal Diseases; Retinal Photoreceptors; Role; Scientist; Seminal; System; Testing; Translating; Veterans; Vision; Work; career; clinical care; diabetic; diabetic patient; glycemic control; inhibitor/antagonist; insight; light intensity; macular edema; novel

Diabetic retinopathy remains the leading cause of visual loss in adults in the US, and it is increasing throughout the US and the world as diabetes rapidly affects more people. Although prolonged good glycemic control has been demonstrated to inhibit the development of diabetic retinopathy in patients, this goal is essentially impossible for most diabetics to maintain, so additional means are needed to inhibit the development of diabetic retinopathy. The Kern laboratory focuses on how diabetic retinopathy develops and thus can be inhibited. This research currently focuses on 4 research areas related to the development of diabetic retinopathy, most of which initially were reported by or championed by Dr. Kern and his collaborators: (1) the role of leukocytes and inflammation as a cause of diabetic retinopathy, and the regulation of those pro-inflammatory changes by epigenetic acetylation, (2) the role of retinal photoreceptor cells and vision itself in the development of the retinal vascular leakage and degeneration of diabetic retinopathy, (3) the use of low intensity light to inhibit and reverse diabetic retinopathy, and (4) the use of systems pharmacology of G-Protein Coupled Receptors to inhibit the retinopathy. Discussions are now underway to translate these findings into patients with diabetes.

糖尿病性视网膜病仍然是美国成年人视觉丧失的主要原因，并且正在增加 在整个美国和世界上，糖尿病会迅速影响更多的人。虽然长期良好 已证明血糖控制可以抑制患者糖尿病性视网膜病的发展， 对于大多数糖尿病患者来说，这个目标基本上是不可能的，因此需要其他手段 抑制糖尿病性视网膜病的发展。克恩实验室专注于糖尿病 视网膜病变发展，因此可以抑制。这项研究目前重点关注4个研究领域 与糖尿病性视网膜病的发展有关，其中大多数最初是由OR报告 在克恩博士及其合作者的支持下：（1）白细胞和炎症的作用 糖尿病性视网膜病，以及通过表观遗传乙酰化对这些促炎性变化的调节， （2）视网膜感光细胞和视觉本身在视网膜血管发展中的作用 糖尿病性视网膜病的泄漏和变性，（3）使用低强度光抑制和反向 糖尿病性视网膜病，（4）使用G蛋白偶联受体的系统药理学抑制 视网膜病。现在正在进行讨论，将这些发现转化为糖尿病患者。